Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
373
¥ millionWording
Conditional
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportSecond quarter of the fiscal year ending March 20275 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥35,626 million+1.1%
Operating profit¥2,740 million+3.5%
Ordinary income¥2,862 million+8.5%
Net income¥2,006 million-9.6%
Selling, general and administrative expenses¥140 100 million
Full-year earnings forecast
Net Sales
¥730 100 million+2.6%
Operating profit
¥62 100 million+6.3%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in revenue from the domestic prescription pharmaceuticals business¥360 million
- Increase in revenue from the animal health business¥360 million
- Decline in Overseas Business Revenue¥-335 million
- Decline in Revenue from Other Businesses¥-11 million
- Reduction in transportation, warehousing and other expenses
New initiatives
- Phase III study of AKP-022 (relugolix combination product)
- Phase III study of LPRI-CF113 (drospirenone)
- Specified clinical research on AKP-SMD106 (therapeutic app)
- Confirmatory clinical trial of MCN-009 (therapeutic app)
- Continuation of development and preparation for AKP-009, AKP-021 and AKP-017
Key KPIsA metric the company considers important as a management benchmark.
- Ratio of sales from branded products40.2 %Year on year against the same period last yearIncreased 3.0 percentage points
- Revenue from feed additives and other products¥2,739 millionYear on year against the same period last year+21.8%
- Revenue from veterinary pharmaceuticals¥1,336 millionYear on year against the same period last year-2.5%
- R&D expenses¥4,365 million
Unit price and quantity metricsThese figures show sales broken down by price and volume.
Qualitative descriptions are provided by product regarding changes in drug prices and volume. Actual volume figures are Not disclosedSegment results
Domestic prescription pharmaceuticals business
Sales
¥29,615 million+1.2%
Profit/Loss
¥3,297 million+5.7%
Animal Health Business
Sales
¥4,125 million+9.6%
Profit/Loss
¥276 million-2.2%
Overseas Business
Sales
¥1,798 million-15.7%
Profit/Loss
¥53 million-59.6%
Other businesses
Sales
¥87 million-12.0%
Profit/Loss
¥-2 million
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Second quarter of the fiscal year ending March 2027 |
| Net Sales | ¥35,626 million (YoY +1.1%) |
| Operating profit | ¥2,740 million (YoY +3.5%) |
| Ordinary income | ¥2,862 million (YoY +8.5%) |
| Net income | ¥2,006 million (YoY -9.6%) |
| Selling, general and administrative expenses | ¥140 100 million |
| Full-year earnings forecast | Net Sales ¥730 100 million (YoY +2.6%) / Operating profit ¥62 100 million (YoY +6.3%) |
| Segment results | Domestic prescription pharmaceuticals business Sales ¥29,615 million (YoY +1.2%) / Profit/Loss ¥3,297 million (YoY +5.7%) / Animal Health Business Sales ¥4,125 million (YoY +9.6%) / Profit/Loss ¥276 million (YoY -2.2%) / Overseas Business Sales ¥1,798 million (YoY -15.7%) / Profit/Loss ¥53 million (YoY -59.6%) / Other businesses Sales ¥87 million (YoY -12.0%) / Profit/Loss ¥-2 million |
| Breakdown of Factors Affecting the Change | Factors Increase in revenue from the domestic prescription pharmaceuticals business / Amount ¥360 million, Factors Increase in revenue from the animal health business / Amount ¥360 million, Factors Decline in Overseas Business Revenue / Amount ¥-335 million, Factors Decline in Revenue from Other Businesses / Amount ¥-11 million, Factors Reduction in transportation, warehousing and other expenses / Amount Not disclosed |
| Key KPIs | Indicator name Ratio of sales from branded products / Value 40.2 % / Year on year against the same period last year Increased 3.0 percentage points, Indicator name Revenue from feed additives and other products / Value ¥2,739 million / Year on year against the same period last year ¥21.8 million, Indicator name Revenue from veterinary pharmaceuticals / Value ¥1,336 million / Year on year against the same period last year ¥-2.5 million, Indicator name R&D expenses / Value ¥4,365 million / Year on year against the same period last year Not disclosed |
| Unit price and quantity metrics | Qualitative descriptions are provided by product regarding changes in drug prices and volume. Actual volume figures are Not disclosed |
| New initiatives | Phase III study of AKP-022 (relugolix combination product), Phase III study of LPRI-CF113 (drospirenone), Specified clinical research on AKP-SMD106 (therapeutic app), Confirmatory clinical trial of MCN-009 (therapeutic app), Continuation of development and preparation for AKP-009, AKP-021 and AKP-017 |
Items this document does not state (18)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as the domestic prescription pharmaceuticals business and animal health business remained strong. Operating profit and ordinary profit increased despite a higher cost-of-sales ratio and increased research and development expenses, mainly due to reductions in transportation, warehousing and other expenses. Interim net income decreased, due mainly to an increase in deferred income taxes.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.